-
Chongqing Zhifei Biological’s EC Injection Receives Market Approval in Indonesia
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has announced that it has received market approval in Indonesia for its in-house developed Category 1 drug, the recombinant Mycobacterium tuberculosis fusion protein (EC) injection. This development marks an important milestone for the company as it…
-
Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics
•
Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US and Hong Kong, China, has announced a significant investment of USD 30 million by Chinese internet conglomerate Tencent into Insighta, a Hong Kong-based company specializing in early cancer detection. Insighta represents a substantial joint venture…
-
LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline
•
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of a Series C1 financing round, raising RMB 300 million (USD 42.1 million). The funding round was led by Sino Biopharmaceutical Ltd (HKG: 1177), with significant contributions from Shanghai Pudong Venture Capital, Zhangjiang Haoheng Innovative Equity…
-
Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals
•
Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the third quarter of 2024, highlighting a robust 9.4% year-on-year sales growth in constant currency terms, reaching USD 10.64 billion. The Established Pharmaceuticals segment recorded a 2.7% rise in Q3 to USD 1.406 billion, with emerging…
-
Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset
•
Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement with Swiss pharmaceutical giant Novartis (NYSE: NVS), according to the Xinhua News Agency. Under this deal, Novartis will acquire the global exclusive rights to develop and commercialize one of Baiyu’s small molecule anti-tumor assets, the…
-
Cryofocus Medtech Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D
•
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the First Affiliated Hospital of Guangzhou Medical University have entered into a collaborative agreement to contribute to the Guangzhou Lab’s project establishment and management. Guangzhou Lab is a cutting-edge research institution dedicated to the prevention and…
-
Kintor Pharmaceutical Initiates Phase II/III Trial for KX-826 Tincture 1.0% in Treating Male Androgenetic Alopecia
•
Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the commencement of patient enrollment in a pivotal Phase II/III study for its KX-826 tincture 1.0%. The study aims to evaluate the efficacy and safety of the treatment in adult males with androgenetic alopecia (AGA) in China.…
-
Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies
•
Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer therapy, has received marketing approval from the US Food and Drug Administration (FDA) for its Optune Lua device. This portable device is now cleared for use in combination with PD-1/PD-L1 inhibitors or docetaxel to treat…
-
Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program
•
French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST), a leading academic institution in China, to include HUST’s PhD students in the Servier Highlighting Innovation through its NEtwork of PhD students and Post-Docs (SHINEDocs) program. This strategic partnership aims to bridge the gap between…
-
Innovent Biologics’ Picankibart Achieves Positive Results in Phase II UC Study
•
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that its Phase II clinical trial for picankibart, an anti-IL-23p19 antibody injection, has successfully met its primary endpoint in Chinese patients with moderately to severely active ulcerative colitis (UC). The multi-center, randomized, double-blinded, placebo-controlled study (NCT05377580)…
-
Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration
•
Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the launch of the China Center of Innovation and Partnership (CIIP) at the SH-INNO incubator in Shanghai. The incubator, established in August this year, is a collaborative effort between Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607),…
-
Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin
•
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ: VTRS), a deal that extends Viatris’s exclusive commercialization rights to sotagliflozin in all markets outside the United States and Europe across all indications. Lexicon Pharmaceuticals retains the exclusive rights to commercialize sotagliflozin within the US…
-
Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial
•
Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from its Phase II/III clinical trial, Vibrance-MG, which evaluated the efficacy of nipocalimab in treating adolescents with generalized myasthenia gravis (gMG) who tested positive for anti-AChR antibodies. The study successfully achieved its primary and secondary endpoints,…
-
NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud
•
The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management of purchasing drugs from the National Reimbursement Drug List (NRDL) outside hospital settings with a prescription. This initiative is intended to enhance oversight of the entire prescription circulation process and combat fraudulent prescriptions and insurance…
-
Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024
•
On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission of demand quantities for the tenth batch of national centralized drug procurement, with a record 81 drugs (263 specifications) making the list. This is poised to set a new record for the highest number of…
-
Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval
•
Alphamab Oncology (HKG: 9966) and CSPC Pharma (HKG: 1093) have jointly announced that their Phase III clinical study application for the combination of HER2 bispecific antibody KN026 and nab-paclitaxel HB1801 (Study Protocol Number: KN026-004) has received approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for neoadjuvant…
-
Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement
•
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health Organization (WHO) Foundation in a significant pledge to enhance access to quality healthcare services for all, particularly targeting vulnerable groups in the Americas who face a heightened risk of suicide. The commitment involves a substantial…
-
J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
•
Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter of 2024, announcing revenues of USD 22.47 billion for the period, marking a 5.2% increase year-on-year in constant currency terms. This growth was comprised of USD 4.58 billion in innovative medicine sales, which expanded by…
-
Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in China, has announced that it has received marketing approvals in India and Hong Kong for its drug toripalimab, used for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The drug will be marketed under…
-
Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced the opening of the Lilly China Medical Innovation Center in Beijing, China, along with plans to establish a Lilly Gateway Labs (LGL). These initiatives are aimed at enhancing clinical trials and bolstering drug research and…
